Danaher to Move into Mass Spec Market Via $1.1B Acquisition of ABI/MDS Sciex Joint Venture

The deal caps months of speculation about Life Tech's plans for the AB Sciex mass spec business following the merger of Invitrogen and ABI last November to create the firm.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.